If, by February, you tire of winter, think of it as being less about endings and more about beginnings—beginnings of the sort described in this issue of GEN. It highlights several fresh starts. Mass spectrometry is beginning to support proteomic research at the single-cell level. Psychedelic drug research, once frozen by legal strictures, is seeing a thaw, one enhanced by the introduction of safer molecules and more convenient regimens. And look for more greening in biomanufacturing, where sustainability metrics are taking root, encouraging investments in technologies that use energy, water, and raw materials more sparingly. Also, continued growth in RNA medicines seems assured now that stability and deliverability challenges are being overcome. Even so dark a subject as antimicrobial resistance admits some light, thanks to innovative companies that are defying the well-known economic disincentives and developing new interventions. Finally, as our A-List of takeover targets indicates, a spring of M&A activity is anticipated.